Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells.
about
Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma.Short androgen receptor poly-glutamine-promoted endometrial cancer is associated with benzo[a]pyrene-mediated aryl hydrocarbon receptor activation.Cancer mortality trends in an industrial district of Shanghai, China, from 1974 to 2014, and projections to 2029.Estrogen-Estrogen Receptor α Signaling Facilitates Bilirubin Metabolism in Regenerating Liver Through Regulating Cytochrome P450 2A6 Expression.Application of EGFR inhibitor reduces circulating tumor cells during transcatheter arterial embolization.Mitochondrial Acetyl-CoA Synthetase 3 is Biosignature of Gastric Cancer Progression.
P2860
Androgen receptor mitigates postoperative disease progression of hepatocellular carcinoma by suppressing CD90+ populations and cell migration and by promoting anoikis in circulating tumor cells.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Androgen receptor mitigates po ...... is in circulating tumor cells.
@en
Androgen receptor mitigates po ...... is in circulating tumor cells.
@nl
type
label
Androgen receptor mitigates po ...... is in circulating tumor cells.
@en
Androgen receptor mitigates po ...... is in circulating tumor cells.
@nl
prefLabel
Androgen receptor mitigates po ...... is in circulating tumor cells.
@en
Androgen receptor mitigates po ...... is in circulating tumor cells.
@nl
P2093
P2860
P356
P1433
P1476
Androgen receptor mitigates po ...... is in circulating tumor cells.
@en
P2093
Chawnshang Chang
Cheng-Lung Hsu
Chun-Chieh Yeh
Hsueh-Chou Lai
Long-Bin Jeng
Pei-Ying Liao
Shang-Fen Huang
Wei-Chun Cheng
Wen-Lung Ma
P2860
P304
46448-46465
P356
10.18632/ONCOTARGET.10186
P407
P577
2016-06-20T00:00:00Z